Atopic dermatitis is a chronic inflammatory skin disease, with inherited predisposition. It has typical morphology and distribution. Patients generally can be controlled with the use of moisturizers and topical steroids. In severe cases, it is recommended the use of alternative management. Cyclosporine is an immunosuppressor drug which inhibit the expression of T activated cells. Many open and placebo-controlled trials have been made evaluating its use, efficacy and security, in adults and children. The results suggest an initial dose of 5-6 mg/kg per day and reducing the amount according to response (load dose and maintenance dose) at long term in order to reach complete remission after withdrawal of treatment and limit adverse effects, like renal toxicity and hypertension. The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.
Arch Dermatol Res
January 2025
Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.
Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.
Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis.
J Am Acad Dermatol
January 2025
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Registries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFCharacterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone.
Exp Dermatol
December 2024
Almirall R+D Centre, Almirall S.A, Sant Feliu de Llobregat, Spain.
Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. The aim of this study was to comprehensively characterise a murine model of dermatitis and assess the similarity with the human disease, as well as to profile clinically relevant AD therapies. Four repeated topical administrations of oxazolone in the auricular skin of sensitised mice induced morphological features compatible with AD, including redness and swelling, as well as histological changes typical of spongiotic (eczematous) dermatitis and increased plasmatic IgE.
View Article and Find Full Text PDFEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Article Synopsis
- The 2024 clinical practice guidelines for atopic dermatitis (AD) focus on effectively managing this condition characterized by itchy, relapsing eczema.
- The primary goal of treatment is to quickly induce remission by reducing skin inflammation and itching, primarily using topical anti-inflammatory medications.
- The updated guidelines introduce five new treatments and emphasize the importance of evaluating research and weighing the pros and cons of various medical options to enhance patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!